Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
AuthorMilani, M; Venturini, S; Bonardi, S; Allevi, G; Strina, C; Cappelletti, MR; Corona, SP; Aguggini, S; Bottini, A; Berruti, A; ...
PublisherIMPACT JOURNALS LLC
University of Melbourne Author/sFox, Stephen
AffiliationSir Peter MacCallum Department of Oncology
Document TypeJournal Article
CitationsMilani, M., Venturini, S., Bonardi, S., Allevi, G., Strina, C., Cappelletti, M. R., Corona, S. P., Aguggini, S., Bottini, A., Berruti, A., Jubb, A., Campo, L., Harris, A. L., Gatter, K., Fox, S. B., Generali, D. & Roviello, G. (2017). Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. ONCOTARGET, 8 (45), pp.78870-78881. https://doi.org/10.18632/oncotarget.20239.
Access StatusOpen Access
Purpose: To identify hypoxia-related biomarkers indicative of response and resistance to epirubicin treatment in patients with locally advanced breast cancer. Patients and Methods: One hundred seventy-six women with T2-4 N0-1 breast tumours were randomly assigned to receive epirubicin 120 mg/m2/1-21 (EPI ARM), epirubicin 120 mg/m2/1-21 + erythropoietin 10.000 IU sc three times weekly (EPI-EPO ARM) and epirubicin 40 mg/m2/w-q21 (EPI-W ARM). Sixteen tumour proteins involved in cell survival, hypoxia, angiogenesis and growth factor, were assessed by immunohistochemistry in pre-treatment samples. A multivariate generalized linear regression approach was applied using a penalized least-square minimization to perform variable selection and regularization. Results: VEGF and GLUT-1 expression were significantly positively associated with complete response (CR) to treatment in all leave-one-out iterations. Bcl-2 expression was inversely correlated with pCR, whilst EPO expression was positively correlated with pathological complete response (pCR). Haemaglobin and HIF-1a nuclear expression were inversely correlated with pCR. HB and HIF-1a expression were associated with a higher risk of relapse and overall survival. Conclusion: Hypoxic biomarkers determines the epirubicin resistance in breast cancer. Assessment of such biomarkers, may be useful for predicting chemosensitivity and also anthracycline-based treatment outcome.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References